Liver lipid content is reduced in rat given 7-day administration of angiotensin II

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 12, Issue 4, 2011, Pages 462-468

  Ishizaka, Nobukazu ^a,b   Hongo, Makiko ^a   Sakamoto, Aiko ^a   Saito, Kan ^a   Furuta, Kyoko ^a   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Angiotensin II; catecholamines; gene expression; hypertension; lipid accumulation

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; FAT DROPLET; FATTY ACID; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LOSARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FATTY ACID OXIDATION; LIPID LIVER LEVEL; LIPOGENESIS; MALE; NONHUMAN; OSMOTIC MINIPUMP; PROTEIN EXPRESSION; RAT;

ADENYLATE KINASE; ANGIOTENSIN II; ANIMALS; AZO COMPOUNDS; BLOTTING, WESTERN; DRUG ADMINISTRATION SCHEDULE; GENE EXPRESSION REGULATION; LIPID METABOLISM; LIVER; PHOSPHORYLATION; RATS; RNA, MESSENGER; STAINING AND LABELING;

EID: 83455201625     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320311415887     Document Type: Article

References (46)

1. Bataller R, Gabele E, Parsons CJ, et al. Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology. 2005 ; 41: 1046-1055 (Pubitemid 40593912)
2. Paizis G, Gilbert RE, Cooper ME, et al. Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J Hepatol. 2001 ; 35: 376-385 (Pubitemid 32844192)
3. Tox U, Steffen HM. Impact of inhibitors of the renin-angiotensin- aldosterone system on liver fibrosis and portal hypertension. Curr Med Chem. 2006 ; 13: 3649-3661 (Pubitemid 44873736)
4. Hirose A, Ono M, Saibara T, et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology. 2007 ; 45: 1375-1381 (Pubitemid 46918321)
5. Ishizaka N, Saito K, Noiri E, et al. Administration of ANG II induces iron deposition and upregulation of TGF-beta1 mRNA in the rat liver. Am J Physiol Regul Integr Comp Physiol. 2005 ; 288: R1063 - R1070
6. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001 ; 121: 91-100 (Pubitemid 32591518)
7. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006 ; 130: 1636-1642
8. Pais R, Pascale A, Fedchuck L, Charlotte F, Poynard T, Ratziu V. Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease. Gastroenterol Clin Biol. 2010 ;:
9. Yoshiji H, Noguchi R, Ikenaka Y, et al. Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat. BMC Res Notes. 2009 ; 2: 70
10. Ueki M, Koda M, Shimizu T, Mitsuta A, Yamamoto T, Murawaki Y. Effect of an angiotensin-II type-1 receptor blocker, candesartan on hepatic fibrosis in chronic hepatitis C: a prospective study. Hepatogastroenterology. 2009 ; 56: 1100-1104
11. Yamaguchi K, Yang L, McCall S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007 ; 45: 1366-1374 (Pubitemid 46918320)
12. Saito K, Ishizaka N, Hara M, et al. Lipid accumulation and transforming growth factor-beta upregulation in the kidneys of rats administered angiotensin II. Hypertension. 2005 ; 46: 1180-1185 (Pubitemid 41533023)
13. Hongo M, Ishizaka N, Furuta K, et al. Administration of angiotensin II, but not catecholamines, induces accumulation of lipids in the rat heart. Eur J Pharmacol. 2009 ; 604: 87-92
14. Ishizaka N, Matsuzaki G, Saito K, Noiri E, Mori I, Nagai R. Expression and localization of PDGF-B, PDGF-D, and PDGF receptor in the kidney of angiotensin II-infused rat. Lab Invest. 2006 ; 86: 1285-1292 (Pubitemid 44789917)
15. Ishizaka N, de Leon H, Laursen JB, et al. Angiotensin II-induced hypertension increases heme oxygenase-1 expression in rat aorta. Circulation. 1997 ; 96: 1923-1929 (Pubitemid 27400754)
16. Ishizaka N, Aizawa T, Yamazaki I, et al. Abnormal iron deposition in renal cells in the rat with chronic angiotensin II administration. Lab Invest. 2002 ; 82: 87-96 (Pubitemid 34072649)
17. Aizawa T, Ishizaka N, Taguchi J, et al. Heme oxygenase-1 is upregulated in the kidney of angiotensin II-induced hypertensive rats: possible role in renoprotection. Hypertension. 2000 ; 35: 800-806 (Pubitemid 30165329)
18. Hongo M, Ishizaka N, Furuta K, et al. Administration of angiotensin II, but not catecholamines, induces accumulation of lipids in the rat heart. Eur J Pharmacol. 2008 ; 604: 87-92
19. Ohno T, Horio F, Tanaka S, Terada M, Namikawa T, Kitoh J. Fatty liver and hyperlipidemia in IDDM (insulin-dependent diabetes mellitus) of streptozotocin-treated shrews. Life Sci. 2000 ; 66: 125-131 (Pubitemid 30025459)
20. Sun L, Halaihel N, Zhang W, Rogers T, Levi M. Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem. 2002 ; 277: 18919-18927 (Pubitemid 34952453)
21. Ueno M, Suzuki J, Zenimaru Y, et al. Cardiac overexpression of hormone-sensitive lipase inhibits myocardial steatosis and fibrosis in streptozotocin diabetic mice. Am J Physiol Endocrinol Metab. 2008 ; 294: E1109 - E1118
22. Yu BC, Chang CK, Ou HY, Cheng KC, Cheng JT. Decrease of peroxisome proliferator-activated receptor delta expression in cardiomyopathy of streptozotocin-induced diabetic rats. Cardiovasc Res. 2008 ; 80: 78-87
23. Matsuzaka T, Shimano H, Yahagi N, et al. Insulin-independent induction of sterol regulatory element-binding protein-1c expression in the livers of streptozotocin-treated mice. Diabetes. 2004 ; 53: 560-569 (Pubitemid 38270623)
24. Ishizaka N, Hongo M, Matsuzaki G, et al. Effects of the AT(1) receptor blocker losartan and the calcium channel blocker benidipine on the accumulation of lipids in the kidney of a rat model of metabolic syndrome. Hypertens Res. 2010 ; 33: 263-268
25. Viollet B, Foretz M, Guigas B, et al. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J Physiol. 2006 ; 574: 41-53 (Pubitemid 43905795)
26. Yang J, Maika S, Craddock L, King JA, Liu ZM. Chronic activation of AMP-activated protein kinase-alpha1 in liver leads to decreased adiposity in mice. Biochem Biophys Res Commun. 2008 ; 370: 248-253
27. Hagstrom-Toft E, Thorne A, Reynisdottir S, et al. Evidence for a major role of skeletal muscle lipolysis in the regulation of lipid oxidation during caloric restriction in vivo. Diabetes. 2001 ; 50: 1604-1611 (Pubitemid 33639601)
28. van der Meer RW, Hammer S, Smit JW, et al. Short-term caloric restriction induces accumulation of myocardial triglycerides and decreases left ventricular diastolic function in healthy subjects. Diabetes. 2007 ; 56: 2849-2853 (Pubitemid 350223617)
29. Hammer S, van der Meer RW, Lamb HJ, et al. Progressive caloric restriction induces dose-dependent changes in myocardial triglyceride content and diastolic function in healthy men. J Clin Endocrinol Metab. 2008 ; 93: 497-503 (Pubitemid 351240822)
30. Brink M, Wellen J, Delafontaine P. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J Clin Invest. 1996 ; 97: 2509-2516 (Pubitemid 26187338)
31. Brink M, Price SR, Chrast J, et al. Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. Endocrinology. 2001 ; 142: 1489-1496 (Pubitemid 32299677)
32. Song YH, Li Y, Du J, Mitch WE, Rosenthal N, Delafontaine P. Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest. 2005 ; 115: 451-458 (Pubitemid 40385487)
33. Cabassi A, Coghi P, Govoni P, et al. Sympathetic modulation by carvedilol and losartan reduces angiotensin II-mediated lipolysis in subcutaneous and visceral fat. J Clin Endocrinol Metab. 2005 ; 90: 2888-2897 (Pubitemid 40686340)
34. Kather H, Wieland E, Fischer B, Wirth A, Schlierf G. Adrenergic regulation of lipolysis in abdominal adipocytes of obese subjects during caloric restriction: reversal of catecholamine action caused by relief of endogenous inhibition. Eur J Clin Invest. 1985 ; 15: 30-37 (Pubitemid 15126850)
35. Du J, Peng T, Scheidegger KJ, Delafontaine P. Angiotensin II activation of insulin-like growth factor 1 receptor transcription is mediated by a tyrosine kinase-dependent redox-sensitive mechanism. Arterioscler Thromb Vasc Biol. 1999 ; 19: 2119-2126 (Pubitemid 29422243)
36. Ma Y, Zhang L, Peng T, et al. Angiotensin II stimulates transcription of insulin-like growth factor I receptor in vascular smooth muscle cells: role of nuclear factor-kappaB. Endocrinology. 2006 ; 147: 1256-1263 (Pubitemid 43244358)
37. Ishizaka N, Alexander RW, Laursen JB, et al. G protein-coupled receptor kinase 5 in cultured vascular smooth muscle cells and rat aorta. Regulation by angiotensin II and hypertension. J Biol Chem. 1997 ; 272: 32482-32488 (Pubitemid 28011933)
38. Toblli JE, Munoz MC, Cao G, Mella J, Pereyra L, Mastai R. ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. Obesity (Silver Spring). 2008 ; 16: 770-776 (Pubitemid 351465631)
39. Fujita K, Yoneda M, Wada K, et al. Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Dig Dis Sci. 2007 ; 52: 3455-3464 (Pubitemid 350077187)
40. Yamamoto E, Dong YF, Kataoka K, et al. Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition. Hypertension. 2008 ; 52: 573-580
41. Ran J, Hirano T, Adachi M. Chronic ANG II infusion increases plasma triglyceride level by stimulating hepatic triglyceride production in rats. Am J Physiol Endocrinol Metab. 2004 ; 287: E955-961
42. Ran J, Hirano T, Adachi M. Angiotensin II infusion increases hepatic triglyceride production via its type 2 receptor in rats. J Hypertens. 2005 ; 23: 1525-1530 (Pubitemid 41104824)
43. Wei Y, Clark SE, Morris EM, et al. Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. J Hepatol. 2008 ;:
44. Wei Y, Clark SE, Thyfault JP, et al. Oxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic Ren2 rats. Am J Pathol. 2009 ; 174: 1329-1337
45. Huisamen B, Perel SJ, Friedrich SO, Salie R, Strijdom H, Lochner A. ANG II type I receptor antagonism improved nitric oxide production and enhanced eNOS and PKB/Akt expression in hearts from a rat model of insulin resistance. Mol Cell Biochem. 2011 ; 349: 21-31
46. Ogihara T, Asano T, Ando K, et al. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension. 2002 ; 40: 872-879 (Pubitemid 35434909)